- 1 Title: Mutation-specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of
- 2 Variants of Concern and the Identification of a Newly Emerging Variant with Spike
- 3 L452R Mutation

7

12

- 5 Huanyu Wang<sup>1,2</sup>, Sophonie Jean<sup>1,2</sup>, Richard Eltringham<sup>1,2</sup>, John Madison<sup>1,2</sup>, Pamela
- 6 Snyder<sup>2</sup>, Huolin Tu<sup>2</sup>, Daniel M. Jones<sup>2\*</sup>, Amy L. Leber<sup>1,2,3\*#</sup>
- <sup>1</sup>Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital,
- 9 Columbus, OH
- <sup>2</sup>Department of Pathology, The Ohio State University, Columbus, OH
- <sup>3</sup>Department of Pediatrics, The Ohio State University, Columbus, OH
- 13 \*Contributed equally
- #Corresponding author: Amy L. Leber, Department of Pathology and Laboratory
- Medicine, Nationwide Children's Hospital. Columbus, OH. Email:
- 16 Amy.Leber@nationwidechildrens.org, phone: 1-614-722-5445
- 18 Running title: SARS-CoV-2 VOC Screening
- 19 Keywords: SARS-CoV-2, variant screening, newly emerging SARS-CoV-2 variant

#### **Abstract**

The emergence of more transmissible and/or more virulent SARS-CoV-2 variants of concern (VOCs) has triggered intensive genomic surveillance, which is costly and difficult to sustain operationally over the long-term. To address this problem, we developed a set of four multiplex mutation-specific PCR-based assays with same-day reporting that can detect five VOCs and three variants of interest (VOIs), as defined in the March 2021 guidelines from the United States (US) Centers for Disease Control and Prevention. The screening results were compared to the whole genome sequencing (WGS) and showed 100% concordance for strain typing for B.1.1.7 (25) and P.1 (5) variants using Spike (S) mutations N501Y, E484K and H69\_V70del assays. The S L450R assay, designed to detect the B.1.427/429 VOCs, also identified multiple isolates of a newly emerging multiply-mutated B.1.526.1 variant that is now rapidly increasing in the Eastern US. PCR approaches can be easily adopted in clinical laboratories, provide rapid screening methods to allow early detection of newly emergent variants and to efficiently triage cases for full genomic sequencing.

## Introduction

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

The novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has evolved considerably in the last six months. Most mutations of interest occur in the Spike (S) protein, the viral protein that binds to the Angiotensin Converting Enzyme 2 (ACE2) cell receptor to initiate the attachment of the virus. Beginning in late 2020, several biologically significant S mutations were shown to be associated with increased transmissibility and virulence, diminished protection by antibodies from convalescent or vaccinated anti-sera as well as decreased response to monoclonal antibody treatment. Therefore, strategies to cost-effectively monitor for shifts in SARS-CoV-2 variants are needed. Three variants of concern (VOCs) with multiple mutations in the S gene have been identified as particularly concerning. The B.1.1.7 (501Y, V1) variant emerged in England and rapidly became the dominant variant in the UK and has now spread to more than 50 countries [1]. B.1.1.7 contains 8-13 different S mutations, including, N501Y in the receptor binding domain (RBD). Studies suggested that it may be associated with higher transmissibility and increased virulence [2, 3]. The B.1.3.5.1 (510Y. V2) variant was first reported in late 2020 in South Africa [4] and variant P.1 (20J/501Y.V3) arose in November 2020 in Brazil. The three spike mutations (K417N/T, E484K and N501Y) carried by both the Brazil and South African variants are associated with increased binding to the human ACE 2 receptor, are more transmissible and mediate partial escape from the protective humoral immunity resulting from prior infection or vaccination [5-7].

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

In March 2021, the US Centers for Disease Control and Prevention (CDC) included B.1.427/B.1.429 as an additional VOC due to its rapid rise in incidence, and introduced the "variant of interest" (VOI) category to encompass strain mutations that might override neutralizing antibody responses, principally S E474K [8, 9]. B.1.427/B.1.429 carries the S L452R mutation which appears linked to the increased transmissibility of this strain [10]. S L452R may be associated with reduction in neutralization using convalescent, post-vaccination sera and resistance to the neutralization by some monoclonal antibodies that have acquired emergency use authorization for treatment [10-12]. The emergence of these VOC highlights that enhanced surveillance is urgently needed. Real time identification of both VOC and VOI will have significant impact not only on management of this on-going pandemic but also patient care. However, this is not possible without local sequencing capacity, which is not always available or may be limited in throughput capacity; WGS is also costly and takes considerable time to complete. An accurate screening strategy would allow the selective use of WGS by targeting samples of interest. This would maximize the use of WGS and broaden the clinical laboratories able to actively participate in identification of VOC. Here, we developed reverse-transcriptase real time PCR (rt-PCR) based assays to screen for spike protein deletions 69-70, 242-244 and mutations N501Y, E484K and L452R in clinical samples known to be positive for SARS-CoV-2. The pattern of positivity accurately typed each VOC (as confirmed by genomic sequencing) except for B.1.427/429 where the majority of cases detected (in March-April 2021) corresponded to a newly emerging multiple mutated variant (previously types as B.1.526.1).

### **Materials and Methods**

**Study Samples** 

Nasopharyngeal swab samples were collected from pediatric patients and employees of Nationwide Children's Hospital, Columbus, Ohio. A flocked NP swab was used and placed into viral transport media for transport to the laboratory for testing by a SARS-CoV2 PCR assay. This surveillance study utilized residual sample for assay validation and was thus exempt human subject research. The set comprised 247 samples. including 156 SARS-CoV-2 positive swabs from February 2<sup>nd</sup> to April 1<sup>st</sup> 2021 that included all adequate samples with Ct values less than 35, and 91 samples collected from Jan 1<sup>st</sup> 2021 to Feb 1<sup>st</sup> 2021 with Ct values less than 35 that were randomly selected from adequate residual samples.

## **Diagnostic SARS-CoV-2 PCR Assay**

which received Emergency Use Authorization by the FDA on April 17, 2020.

(<a href="https://www.fda.gov/media/137424/download">https://www.fda.gov/media/137424/download</a>; accessed March 24, 2021) Briefly, total nucleic acid was obtained by extraction using the NucliSENS easyMag platform (bioMerieux, Durham, NC) and 5µL of the eluate was added to a 25 µL total volume reaction mixture [ 5µl of 1XTaqPath 1-Step RT-qPCR Master Mix, CG (Thermo Fisher Scientific, Waltham, MA), 1.5 µl of RT-PCR primer/probe set (N1 or N2, 2019-nCoV kit, Integrated DNA Technologies, Coralville, IA) and 13.5µl nuclease-free water]. The RT-PCR was carried out using the Applied Biosystems™ QuantStudio™ 7 Flex Real Time PCR detection system with QuantStudio™ Real-Time PCR software v.1.3 (Thermo

We utilized a laboratory-developed modification of the CDC SARS-CoV-2 rt-PCR assay

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Fisher Scientific, Waltham, MA) with the following running conditions: 25°C for 2min, 50°C for 15 minutes, enzyme activation at 95°C for 2min, and 45 cycles of 95°C for 3 sec and 55°C for 30 sec. **Mutation Screening Assays** SARS-CoV-2 positive sample were screened by four multiplex rt-PCR assays, with results available same day. The sequences for detection of Δ69-70 were adapted from a multiplex real-time RT-PCR assay for detection of SARS-CoV-2[13]. The probe overlaps with the sequences that encode amino acids 69-70, therefore, a negative result for this assay predicts the presence of a detection S 69-70 in the sample. Using a similar strategy, a primer/probe set that targets the detection S Δ242-244 was designed and was run in the same reaction with S Δ69-70. In addition, three separate assays were designed to detect spike mutations 501Y, 484K and 452R and wild types 501N, 484E and 452L. The sequences for each oligonucleotide are presented in Table 1. Briefly, 5µL of the total nucleic acid eluate was added to a 20 µL total volume reaction mixture [1XTaqPath 1-Step RT-qPCR Master Mix, CG (Thermo Fisher Scientific, Waltham, MA), 0.9µM of each primer and 0.2µM of each probe]. The RT-PCR was carried out using the ABI 7500 thermocycler (Life Technologies, Grand Island, NY). The N501Y, E484K and L452R assays were carried out with the following running conditions: 25°C for 2 min, then 50°C for 15 min, followed by 10 min at 95°C, 45 cycles of 95°C for 15s and 65°C for 1 min. The  $\Delta 69-70/\Delta 242-244$  assay was run under the following

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

conditions: 25°C for 2 min, then 50°C for 15 min, followed by 10 min at 95°C, 45 cycles of 95°C for 15s and 60°C for 1 min. Samples that yielded negative result(s) in  $\Delta 69-70/\Delta 242-244$  assay or were positive for 501YP2, 484KP2 and L452RP2 were considered screen-positive and assigned to a VOC based on the scoring in Table 2. All screening positive samples and a similar number of screening negative samples collected in the same period were sent for WGS. **SARS-CoV-2 Whole Genome Sequencing** Previously extracted RNA underwent 1st and 2nd strand cDNA synthesis (NEBNext® Ultra# II Non-Directional RNA Second Strand Synthesis Module, NEB, Ipswich, MA) followed by sequencing using two different clinically validated amplicon-based methods. Most samples were analyzed using the SARS-CoV-2 Research Panel primers (ThermoFisher) on the Ion Chef-S5 sequencer (ThermoFisher) per manufacturer's conditions. The remaining sequences were analyzed using the CovidSeg kit (Illumina, San Diego, CA) per manufacturer's conditions and sequenced on the NextSeq 550 sequencer (Illumina). Strain typing on the two different assays were cross-validated using a set of 20 SARS-CoV-2 positive and 5 SARS-CoV-2 negative samples. **Genomic Analyses and Strain Typing** Sequence analysis tools include custom pipelines utilizing GATK and Mutect2 (Broad Institute) and Dragen SARS-COVID variant detection (for CovidSeq assay). Adequate sequencing required coverage of strain-distinguishing areas of the ORF1a, S, N and ORF8 genes at least 100X depth. All but two sequences in this series yielded adequate strain-typable sequences and no sample contained a mixed population of

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

viruses. Viral sequences were strain-typed using Pangolin (https://cov-lineages.org) and NextStrain criteria (https://nextstrain.org/blog/2021-01-06-updated-SARS-CoV-2-cladenaming). Novel combinations of mutations were investigated for similar viruses using the laboratory internal sequence database (1110 sequences as of 4/1/21) and/or the GISAID database (accessed at gisaid.org). Results Correlation of RT-PCR Mutation Screen Results with Whole Genome SARS-CoV-2 Sequencing From Jan 2021 to April 1<sup>st</sup>, we screened 247 samples for VOC and VOI. Among all screened samples, 128 samples were collected from hospital employees, 91 samples were from outpatients and 28 samples were from hospitalized or emergency room patients. A total of 102 samples were sent for WGS. There were 61 screen-positive samples and 41 screen-negative samples sent for WGS. The screening assays were 100% concordant with the WGS for identification of the three RBD mutation (Table 3). The screening assays successfully predicted the presence of all 25 B.1.1.7 and 5 P.1 VOCs (Table 4). Six samples were positive for only the E484K mutation, with five confirmed to be P.2 and one confirmed to be R.1 by WGS. The screening PCR assays had 100% negative agreement when compared to WGS for prediction of these VOCs and VOIs. Sixteen of the samples were positive only for N501Y and were shown by sequencing to be the 20G/501Y strain we have previously described [14] in fourteen and B.1.1.165 in two. Eight samples were screen-

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

positive for S L452R with 3 of them strain typed as B.1.427/B.1.429, and five representing the newly emerging B.1.526.1 variant described in more detail below. All negative screening samples were negative for VOC or VOI by WGS. Forty one screen-negative samples were found to be commonly encountered B.1 or B.1.2 with no S mutations of concern. No sample was positive only for S deletion  $\Delta 69-70$  or S deletion  $\Delta$ 242-244. One sample that had suboptimal amplification in the  $\Delta$ 69-70 assay was found to have a mutation in the primer binding site. Timing of Emergence of PCR-detected Variants of Concern Matches Results from From January to April 1st 2021, we screened 247 SARS-CoV-2 samples. As shown in Figure 1, the earliest case with B.1.1.7 was identified in mid-February 2021, subsequently, cases of B.1.1.7 were found in every batch of samples tested. The earliest case with P.1 was also collected in mid-February 2021, with a substantial increase in P.1 positive cases over time. The first B.1.429 in our population appeared in late March 2021. In the third week of February, 2021, one sample collected from a patient was found to carry both N501Y and E484K mutations and was sent for WGS. The sequences of this sample closely relate to Brazil P.1. VOC and was designated into lineage B.1.1.28 and was the first P.1. sample reported in the state of Ohio (EPI\_ISL\_1164183). In the same week, another sample collected from an employee was found to carry  $\Delta 69-70$  and E484K mutation that represent the first Ohio sample of the emerging B.1.525 lineage (EPI\_ISL\_1203843).

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

Three of the L452R-bearing viruses in our screen were documented to be B.1.427/429. This VOC first appeared in California in July 2020 (EPI\_ISL\_765997) and is characterized by Spike mutations S13I, W152C as well as L452R. In early November 2020, B.1.427/429 became the predominant strain in Southern California before spreading throughout the United States in December-January 2020. The observed increase in B.1.427/429 in our study matches that seen in CDC totals from WGS in Ohio. **Emergence of the B.1.526.1 L452R-containing variant** Unlike the other VOC in our study, we noted that a positive screen for L452R still required sequencing to definitively strain type. This was due to the emergence in late March in our area of another L452R-bearing strain besides the B.1.427/429 VOC. Five of 8 (62.5%) screen-positive L452R-containing viruses from March 2021 represented a newly emerging strain that has been tentatively strain-typed as B.1.526.1 (Table 5). The diagnostic PCR Ct values are presented in Table 6. In addition to L452R, this strain has four additional S mutations, D80G, F157S, T859N and D950H, which include both N-terminal and stalk variants. It shares with B.1.427/429, the 20C/B.1 backbone as indicated by mutations ORF1 T265I, ORF1a A1679S, ORF1a L3201P, ORF1b P314L, ORF3a Q57H and S D614G. Based on the frequency of the Spike mutations in B.1.526.1 viruses reported in GISAID as of April 10 2021, the variant likely developed from a L452R-bearing B.1 strain, then acquired F157S, D80G and Y145del, followed by T859 and D950H. The few GISAID sequences that do not follow this pattern are reported as suboptimal quality studies. A small number (n=7) of B.1.526.1 viruses contain D80N/N81Y instead of D80G. The

earliest GISAID-reported instances of B.1.526.1 were two sequences from New York
City collected on 12/18/20 (EPI\_ISL\_794288 and EPI\_ISL\_794289), with all sequences
through 2/5/21 reported from New York City (mostly, Bronx county). Spread to 11 other
states (including Ohio) occurred in February and then throughout the United States in
March, 2021. Given that 578 of 2369 (24.4%) viruses typed as B.1.526.1 lineage in
GISAID do not contain any of the above Spike mutations, lineage classification may be
provisional.

A comparison of the incidence of the B.1.427/429 and B.1.526.1 strains in GISAID
during 2021 shows a declining proportion of the forms and increases in the latter in
March matching our observations in Columbus (Figure 2).

#### **Discussion**

We describe a multiplex, mutation-specific rt-PCR-based strategy to rapidly and reliably screen for SARS-CoV2 genetic variants in a clinical laboratory setting. These assays detect all three target RBD spike mutations and have a 100% concordance with the strains identified by WGS. Using simple rules based on the combination of assay results, the strategy successfully identified all B.1.1.7 and P.1 samples, with the frequencies of each of the VOCs detected matching their emergence by the CDC and Department of Health WGS surveillance studies over the last several months. Using this strategy, we successfully identified and reported the first P.1 variant in Ohio from a patient which suggested that the P.1 variant has already spread in the community; a finding confirmed in subsequent reports.

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

However, for S L452R-positive screens, we noted that both B.1.427/429 VOC and a newly emerging B.1.526.1 strain were detected [15]. The latter samples were identified only in the latest March 2021 samples and match the observed spread of GISAIDreported B.1.526.1 viruses outside of the state of New York. Although both of these strains show multiple mutations in other areas of the Spike gene, the L452R mutation is their only RBD mutation. This mutation has been associated with resistance to neutralization by RBD-binding monoclonal antibodies, such as bamlanivimab [12], which has affected the use of these therapies. The single RBD mutation in these two strains is in contrast to other VOC which besides N501Y and E484K (in two of them, P.1 and B.1.351) show additional mutations known to alter receptor binding affinity [16-18]. It will be important to monitor sequential samples from these strains to see if the acquire additional RBD mutations, particularly at antibody escape residues, as B.1.1.7 viruses have done in some cases. Mutation-specific PCR assays can be run in real-time with a turn-around time of several hours, which is significantly faster than WGS and in this configuration can be performed cost-effectively on all PCR-positive samples. This broader approach is clearly superior to the use of other VOC indicators such as S-gene dropout in the 3-target diagnostic RT-PCR assay (TagPath kit, Thermo Fisher Scientific, Waltham, MA) which has been reported by others as a method to detect the H69-V70del associated with B.1.1.7 [9, 19-22] . Similarly, PCR-based N501Y and E484K mutation-specific assays are sensitive for detection of P.1 and B.1.351 [23, 24], respectively, but will not definitively distinguish them as an increasing number of VOIs also bear these mutations. In this study, we could not fully evaluate all scoring combinations, particularly the use of co-positivity for

N501Y and  $\Delta$ 242-244 as a marker for the B.1.351 VOC, as we did not find any examples of this virus in our test population. However, the combination of assay presented here has more diagnostic utility in distinguishing VOC and VOI than single mutation-specific PCR approaches. There are some limitations to a reflex mutant-PCR panel strategy. First, many diagnostic PCR platforms can deplete swab material, leaving an inadequate volume of residual sample for a multi-tube mutation screen. These assays also did not perform well when the diagnostic PCR Ct value is greater than 35 cycles. However, this problem is shared with amplicon-based WGS [25]. As demonstrated by our finding with L452Rpositives, new variants of SARS-CoV-2 are still emerging so confirmation of some results by WGS will still be required. Finally, to evaluate for novel mutations, a sampling of screen-negative specimens for WGS will be an important component of a full surveillance strategy. In summary, the use of a panel of multiplex, mutant-specific rt-PCR assays represents an ideal balance of cost, turn-around-time and accuracy for detecting SARS-CoV-2 VOC and VOI. The technology is amenable for use in a larger number of clinical laboratories than next-generation sequencing. In our current environment requiring rapid strain typing to guide both treatment decisions and public health measures, such a rapid and accessible approach will be essential.

## **Acknowledgments**

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

For the GIS sequences in Figure 2, we acknowledge the originating laboratories responsible for obtaining the specimens and the submitting laboratories where genetic sequence data were generated and shared via the GISAID Initiative.

### Reference

- 281 1. Alpert, T., et al., Early introductions and community transmission of SARS-CoV-2 variant
- 282 B.1.1.7 in the United States. medRxiv, 2021.
- 283 2. Challen, R., et al., Risk of mortality in patients infected with SARS-CoV-2 variant of
- 284 concern 202012/1: matched cohort study. BMJ, 2021. **372**: p. n579.
- 285 3. Davies, N.G., et al., Increased mortality in community-tested cases of SARS-CoV-2 lineage
- 286 *B.1.1.7.* Nature, 2021.
- 4. Tegally, H., et al., Emergence of a SARS-CoV-2 variant of concern with mutations in spike
- 288 *glycoprotein.* Nature, 2021.
- 289 5. Zucman, N., et al., Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A
- 290 case report. Clin Infect Dis, 2021.
- 291 6. Moyo-Gwete, T., et al., SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing
- 292 antibodies. bioRxiv, 2021.
- 293 7. Garcia-Beltran, W.F., et al., Circulating SARS-CoV-2 variants escape neutralization by
- vaccine-induced humoral immunity. medRxiv, 2021.
- 295 8. *Centers for Disease Control and Prevention*. 2021; Available from:
- 296 https://www.cdc.gov/coronavirus/2019-ncov/.
- 9. Annavajhala, M.K., et al., A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in
- 298 *New York.* medRxiv, 2021.
- 299 10. Zhang, W., et al., Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA,
- 300 2021.

301	11.	Deng, X., et al., Transmission, infectivity, and antibody neutralization of an emerging
302		SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv, 2021.
303	12.	Liu, Z., et al., Identification of SARS-CoV-2 spike mutations that attenuate monoclonal
304		and serum antibody neutralization. Cell Host Microbe, 2021. <b>29</b> (3): p. 477-488 e4.
305	13.	Zhen, W. and G.J. Berry, Development of a New Multiplex Real-Time RT-PCR Assay for
306		Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection. J Mol Diagn,
307		2020. <b>22</b> (12): p. 1367-1372.
308	14.	Tu H, A.M., Kubatko L, Hunt M, Pan X, Ru P, Garee J, Thomas K, Mohler P, Pancholi P,
309		Jones D. , Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y
310		in Clinical Samples in Columbus Ohio. bioRxiv, 2021.
311	15.	Greaney AJ, S.T., Barnes CO, Weisblum Y, Schmidt F, Caskey M, Gaebler C, Cho A,
312		Agudelo M, Finkin S, Wang Z, Mutational escape from the polyclonal antibody response
313		to SARS-CoV-2 infection is largely shaped by a single class of antibodies. bioRxiv, 2021.
314	16.	Starr, T.N., et al., Prospective mapping of viral mutations that escape antibodies used to
315		treat COVID-19. Science, 2021. <b>371</b> (6531): p. 850-854.
316	17.	Greaney, A.J., et al., Comprehensive mapping of mutations in the SARS-CoV-2 receptor-
317		binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host
318		Microbe, 2021. <b>29</b> (3): p. 463-476 e6.
319	18.	Greaney, A.J., et al., Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-
320		Binding Domain that Escape Antibody Recognition. Cell Host Microbe, 2021. 29(1): p. 44-
321		57 e9.

202012/01 and other variants with spike deletion H69-V70, France, August to December 2020. Euro Surveill, 2021. <b>26</b> (3).  10	า
325 20. Ibba, G., et al., <i>A straightforward molecular strategy to retrospectively investigate the spread of SARS-CoV-2 VOC202012/01 B.1.1.7 variant.</i> J Infect Dev Ctries, 2021. <b>15</b> (2):	er
326 spread of SARS-CoV-2 VOC202012/01 B.1.1.7 variant. J Infect Dev Ctries, 2021. <b>15</b> (2):	
242 246	p.
327 242-246.	
328 21. Gaymard, A., et al., Early assessment of diffusion and possible expansion of SARS-CoV-	2
329 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to	
330 <i>March 2021</i> . Euro Surveill, 2021. <b>26</b> (9).	
331 22. Borges, V., et al., <i>Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from</i>	
nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data	
333 Portugal, week 49 2020 to week 3 2021. Euro Surveill, 2021. <b>26</b> (10).	
334 23. Banada, P., et al., A Simple RT-PCR Melting temperature Assay to Rapidly Screen for	
Widely Circulating SARS-CoV-2 Variants. medRxiv, 2021.	
336 24. Matic, N., et al., Rapid Detection of SARS-CoV-2 Variants of Concern, Including	
337 B.1.1.28/P.1, in British Columbia, Canada. Emerg Infect Dis, 2021. <b>27</b> (6).	
25. Charre, C., et al., Evaluation of NGS-based approaches for SARS-CoV-2 whole genome	
characterisation. Virus Evol, 2020. <b>6</b> (2): p. veaa075.	
340	

Figure 1. Shifts in the proportions of SARS-CoV-2 strains from January to March 2021.

Figure 2. Comparison of incidence in the United States of B.1.427/429 and B.1.526.1 in 2021. Spike L452R-bearing SARS-CoV-2 genomes from North America were downloaded from GISAID and strain type confirmed by mutation pattern. Graphed is the proportion of B.1.427/429 versus B.1.526 viruses during each 2-week period in 2021.

## Table 1: Mutation-specific reverse-transcriptase PCR: primers and probes.

Assays	Oligo name	Sequences
S gene Δ69-70/ Δ242-244	S Δ69-70 F	5'-TCAACTCAGGACTTGTTCTTAC-3'
multiplex assay	S Δ69-70 R	5'-TGGTAGGACAGGGTTATCAAAC-3'
	S Δ69-70 P	5'- FAM-TGGTCCCAGAGACATGTATAGCAT- BHQ1-3'
	S Δ242-244 F	5'- TGGTAGATTTGCCAATAGGTATTAACA -3'
	S Δ242-244 R	5'- CTGAAGAAGAATCACCAGGAGTCA -3'
	S Δ242-244 P	5' - VIC-ACTTTACTTGCTTTACATAGAAG-MGB -3'
S gene N501Y assay	S N501Y F	5'- TGTTACTTTCCTTTACAATCATATGGTTTC -3'
doddy	S N501Y R	5'-GAAAGTACTACTCTGTATGGTTGGTAACC - 3'
	S 501N P1	5'-VIC-CAACCCACTaATGGTGTT-MGB-3'
	S 501Y P2	5'-FAM-CAACCCACTtATGGTGTT-MGB3'
S gene E484K assay	S E484K F	5'-CAGGCCGGTAGCACCCTT-3'
uoody	S E484K R	5'-GTTGGAAACCATATGATTGTAAAGGA-3'
	S 484E P1	5'-FAM-TAATGGTGTTgAAGGTTT-MGB -3'
	S 484K P2	5'-VIC-TGTAATGGTGTTaAAGGT –MGB-3'
S gene L452R assay	S L452R F	5'-TGATAGATTTCAGTTGAAATATCTCTCTCA-3'
	S L452R R	5'-AATCTTGATTCTAAGGTTGGTGGTAATTAT-3'
	S 452L P1	5' FAM-CCTAAACAATCTATACaGGTAA-MGB-3'
	S 452R P2	5'-VIC-CTAAACAATCTATACcGGTAAT-MGB-3'

## Table 2: Strain-typing rules for interpretation of screening results.

354

	Mutations						
	Δ69-70	Δ242-244	N501Y	E484K	L452R		
Variants of Concern		l			L		
B.1.1.7	Pos	Neg	Pos	Neg	Neg		
B.1.351	Neg	Pos	Pos	Pos	Neg		
P.1	Neg	Neg	Pos	Pos	Neg		
B.1.427/ B. 1.429 or B.1 80G-157L-4	Neg	Neg	Neg	Neg	Pos		
Variants of Interest	1		ı				
B.1.525	Pos	Neg	Neg	Pos	Neg		
R.1, P.2, B.1.525, B.1.526,	Neg	Neg	Neg	Pos	Neg		
B.1.2/501Y or B.1.1.165	Neg	Neg	Pos	Neg	Neg		

## Table 3: Performance of the Screening Assays for Detection of RBD Mutations.

356

357

358

		WGS n=102							
	L452R		E484K		N501Y				
		Pos	Neg	Pos	Neg	Pos	Neg		
Screening	Pos	8	0	12	0	46	0		
assays	Neg	0	94	0	90	0	56		
PPA %	100		100		100				
NPA %	100		100		100				

PPA: positive percentage agreement; NPA: negative percentage agreement

363

Table 4: Performance of the screening assays for detection of variants.

		WGS	n=102														
		Varia	Variants of Concern									Variants of Interest					
		B.1.1.7		B.1.351		P.1		B.1.427 or B.1.429		B.1.525		P.2, B.1.526 or R.1		20G/501Y as in Ref 14 or B.1.1.165			
		Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg		
Screening	Pos	25	0	0	0	5	0	3	5\$	1	0	6*	0	16	0		
assays	Neg	0	77	0	102	0	97	0	94	0	101	0	96	0	86		
PPA %		100	<u> </u>	N/A		100		37.5		100		100		100			
NPA %		100		100		100		100		100		100		100			

<sup>\$</sup>All five samples were identified carrying a newly emerged variant: B.1.526.1

PPA: positive percentage agreement; NPA: negative percentage agreement

<sup>\*</sup>Five samples were identified as strain P.2 and one sample was strain R.1

# Table 5: Spike mutations associated with a newly emerged S L452R-containing variant.

Amino acid change	cDNA location	# GISAID*	# B.1.526.1 viruses (%)	Domain	Other lineages commonly showing the mutation
p.Asp80Gly	c.239A>G	587	548 (93.4)	NTD	
p.Phe157Ser	c.470T>C	661	588 (89.0)	NTD	
p.Leu452Arg	c.1355T>G	12,997	608 (4.7)	RBD	B.1.427/429, A.2.5
c.2576C>A	p.Thr859Asn	840	461 (54.9)	CR	B.1.36.9
p.Asp950His	c.2848G>C	459	419 (91.3)	HR1	
4 or 5 of thse S mutations		449	449 (100)		

Abbrevisions: NTD, N-terminal domain; RBD, receptor binding domain; HR1, heptad repeat 1;

368 CR: connecting region.

364

365

366

369

370

\*Data as of 4/10/21

## Table 6: Ct values of the samples carry newly emerged S L452R-containing

## **variant**.

B.1.526.1 Samples	Ct Values				
	N1	N2			
Patient 1	31.8	33.3			
Patient 2	23.2	23.5			
Employee 1	13.6	12.5			
Patient 3	29.2	28.8			
Patient 4	23.4	24.2			




Figure 1. Shifts in the proportions of SARS-CoV-2 strains from January to March 2021.




Figure 2. Comparison of incidence in the United States of B.1.427/429 and B.1.526.1 in 2021.

Spike L452R-bearing SARS-CoV-2 genomes from North America were downloaded from GISAID and strain type confirmed by mutation pattern. Graphed is the proportion of B.1.427/429 versus B.1.526 viruses during each 2-week period in 2021.